Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)

Farolfi, Alberto; Petrone, Micaela; Scarpi, Emanuela; Gallà, Valentina; Greco, Filippo; Casanova, Cláudia; Longo, Lucia; Cormio, Gennaro; Orditura, Michele; Bologna, Alessandra; Zavallone, Laura; Ventriglia, Jole; Franzese, E.; Loizzi, Vera; Giardina, D.; Pigozzi, Eva; Cioffi, Raffaella; Pignata, Sandro; Giorda, Giorgio; Giorgi, Ugo De

doi:10.1007/s11523-018-0574-1

Cited by 45 publications

(47 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…142 SII is a powerful prognostic indicator, which when elevated, confers a poor outcome in patients with various cancers. 143,144 SII is an independent prognostic indicator of poor outcomes for patients with stage III NSCLC and is a superior prognostic indicator to other inflammation-based indices, including NLR and PLR. 130 Its low cost, easy determination, and high reproducibility from a simple complete blood count and differential make SII a promising tool for individualized lung cancer treatment strategies.…”

Section: Systemic Inflammatory Indicators In Mpe Patientsmentioning

confidence: 99%

Making cold malignant pleural effusions hot: driving novel immunotherapies

et al. 2019

View full text Add to dashboard Cite

Malignant pleural effusions, arising from either primary mesotheliomas or secondary malignancies, heralds advanced disease and poor prognosis. Current treatments, including therapeutic thoracentesis and tube thoracostomy, are largely palliative. The immunosuppressive environment within the pleural cavity includes myeloid derived suppressor cells, T-regulatory cells, and dysfunctional T cells. The advent of effective immunotherapy with checkpoint inhibitors and adoptive cell therapies for lung cancer and other malignancies suggests a renewed examination of local and systemic therapies for this malady. Prior strategies reporting remarkable success, including instillation of the cytokine interleukin-2, perhaps coupled with checkpoint inhibitors, should be further evaluated in the modern era.

show abstract

Section: Systemic Inflammatory Indicators In Mpe Patientsmentioning

confidence: 99%

Making cold malignant pleural effusions hot: driving novel immunotherapies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Among them, one concerning cervical cancer was disposed separately cause of providing HRs and survival outcomes for patients with two different treatments [21]. As a consequence, fifteen, nine, and four publications regarding to cervical [19,[21][22][23][24][25][26][27][28][29][30][31][32][33][34], ovarian [35][36][37][38][39][40][41][42][43], and endometrial cancer [44][45][46][47] were enrolled, respectively.…”

Section: Literature Search Results and Characteristicsmentioning

confidence: 99%

“…In the subgroup analyses, three details should be stated initially. In the subgroup of median age, one research [42] provided two different median age (60 and 63) for diverse group. However, this did not influence the classification of subgroup in this data due to the cut-off value of median age was 50 years old.…”

Section: Subgroup Analysis Of Overall Survival and Progression-free Smentioning

confidence: 99%

Prognostic function of platelet-to-lymphocyte ratio in gynecologic cancers: A systematic review and meta-analysis

Fan

Dai

Wang

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Although along with the diagnosis and treatment level enhanced, current situation of the gynecologic malignancies improved, the risk of gynecologic tumor remains high. Nowadays, inflammatory markers increasingly employed as a tumor predictive factor. Herein, we focused on the association between the platelet-to-lymphocyte ratio (PLR) and gynecological cancers, including cervical, ovarian, and endometrial cancer. Methods: In this meta-analysis, we searched systematically on the EMBASE and PubMed databases from June 1, 1989 to May 31, 2019. After excluded some unqualified articles, we calculated the pooled hazard ratio (HR) with 95% confidence interval (CI) mainly to detect the relationship between PLR and prognostic survival, including overall survival (OS) and progression-free survival (PFS). Random-effect model was adopted when I 2 >50% after Higgins I 2 test. Subgroup analysis and funnel plot were used to seek for the possible source of heterogeneity and publication bias, respectively. All statistical tests were two-sided. Results: After a series of searching and selection, twenty-eight literatures containing 8290 participants totally. Among those recruited trials, 26 studies comprising 8109 patients reported HR for OS and 15 researches enrolled 4283 patients for PFS. Overall, a high value of PLR means a worse OS and PFS in women with gynecologic cancer except those with endometrial cancer for OS (pooled HR =1.35, 95% CI =0.73 to 2.53, P =0.33). Subgroup analyses indicated that the source of heterogeneity may be primarily from the sample size, PLR cut-off, study location, published year, and the cut-off year for the study. Publication bias manifested that bias was not evident. Conclusion: Elevated pretreatment PLR portends a poor prognosis among patients with gynecological tumor, as well as in women with cervical and ovarian malignancies for both OS and PFS. However, in patients with endometrial cancer, this connection is broken for OS but still available for PFS.

show abstract

“…NLR, defined as the absolute neutrophil count divided by the absolute lymphocyte count, is probably the most-studied prognostic index. An increased NLR is associated with poor prognosis in several tumors such as breast, lung, pancreatic, colorectal, gastric, urothelial, prostate, ovarian, and kidney cancers [91][92][93]. Neutrophils are known to be able to aid the proliferation and survival of malignant cells, promoting angiogenesis and metastasis.…”

Section: Inflammation As Prognostic Factormentioning

confidence: 99%

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment

Brighi

Farolfi

Conteduca

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

Treatment options for metastatic renal cell carcinoma (RCC) have been expanding in the last years, from the consolidation of several anti-angiogenic agents to the approval of immune checkpoint inhibitors (ICIs). The rationale for the use of immunomodulating agents derived from the observation that RCC usually shows a diffuse immune-cell infiltrate. ICIs target Cytotoxic T Lymphocytes Antigen 4 (CTLA-4), programmed death 1 (PD-1), or its ligand (PD-L1), showing promising therapeutic efficacy in RCC. PD-L1 expression is associated with poor prognosis; however, its predictive role remains debated. In fact, ICIs may be a valid option even for PD-L1 negative patients. The establishment of valid predictors of treatment response to available therapeutic options is advocated to identify those patients who could benefit from these agents. Both local and systemic inflammation contribute to tumorigenesis and development of cancer. The interplay of tumor-immune status and of cancer-related systemic inflammation is pivotal for ICI-treatment outcome, but there is an unmet need for a more precise characterization. To date, little is known on the role of inflammation markers on PD-1 blockade in RCC. In this paper, we review the current knowledge on the interplay between inflammation markers, PD-1 axis, and anti-angiogenic agents in RCC, focusing on biological rationale, implications for treatment, and possible future perspectives.

show abstract

Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)

Abstract: Our results suggest that bevacizumab improves clinical outcome in patients with a high NLR but may be detrimental in those with a high SII.

Cited by 45 publications

References 38 publications

Making cold malignant pleural effusions hot: driving novel immunotherapies

Making cold malignant pleural effusions hot: driving novel immunotherapies

Prognostic function of platelet-to-lymphocyte ratio in gynecologic cancers: A systematic review and meta-analysis

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment

Contact Info

Product

Resources

About